The Leukemia & Lymphoma Society (LLS), a charitable organization founded in 1949, is largest voluntary health organization dedicated to fighting blood cancer in the world. The LLS's mission is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.[4]LLS is headquartered in Rye Brook, New York, with 56 chapters throughout the United States and five chapters in Canada. LLS has six signature fundraising campaigns: Team In Training, the largest charitable endurance training program in the world; Light The Night, an annual series of community-based walkathons; Man & Woman of the Year, a series of annual ten-week long, community-based competitions in which adults raise funds in honour of local children who have survived blood cancer; Students of the Year, an annual series of seven-week long, community-based fundraising competitions amongst high school students; Leukemia Cup Regatta, a series of fundraising sailing events held by yacht clubs across North America; and Pennies for Patients, a programme providing North American elementary and middle schools with access to STEM curricula. In addition to the main campaigns, there is LLS Lifestyle, in which groups and individuals, through their local chapters, can turn any activity or event into a vehicle for fundraising. Acute myeloid leukemia (AML) is a rapidly progressing disease that remains one of the most deadly bloodcancers, killing more than 10,000 Americans a year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – had changed little over the past four decades. In October 2016, LLS launched its Beat AML Master Clinical Trial, a collaborative precision medicine clinical trial that gives patients targeted therapies based on their genetic markers.[5]
LLS is leading the Beat AML Master Clinical Trial [8] and is the first nonprofit cancer organization to sponsor a clinical trial. The trial consists of a collaboration among multiple leading cancer centres and pharmaceutical companies, a clinical research organization, and a genomics analysis company. The protocol for the trial was developed with input from the U.S. Food and Drug Administration (FDA). The Beat AML Master Clinical Trial is expected to eventually include 500 patients and will continue for at least two years at between 15 and 20 clinical sites.
Research Article: Accounting & Marketing
Research Article: Accounting & Marketing
Research Article: Accounting & Marketing
Research Article: Accounting & Marketing
Research Article: Accounting & Marketing
Research Article: Accounting & Marketing
Research Article: Accounting & Marketing
Research Article: Accounting & Marketing
Posters-Accepted Abstracts: Accounting & Marketing
Posters-Accepted Abstracts: Accounting & Marketing
Posters-Accepted Abstracts: Accounting & Marketing
Posters-Accepted Abstracts: Accounting & Marketing
Posters & Accepted Abstracts: Business and Economics Journal
Posters & Accepted Abstracts: Business and Economics Journal
Scientific Tracks Abstracts: Business and Economics Journal
Scientific Tracks Abstracts: Business and Economics Journal
Scientific Tracks Abstracts: Business and Economics Journal
Scientific Tracks Abstracts: Business and Economics Journal
Accounting & Marketing received 487 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 